218 related articles for article (PubMed ID: 22473914)
1. Identification of selective inhibitors of the potassium channel Kv1.1-1.2((3)) by high-throughput virtual screening and automated patch clamp.
Wacker SJ; Jurkowski W; Simmons KJ; Fishwick CW; Johnson AP; Madge D; Lindahl E; Rolland JF; de Groot BL
ChemMedChem; 2012 Oct; 7(10):1775-83. PubMed ID: 22473914
[TBL] [Abstract][Full Text] [Related]
2. A new Kaliotoxin selective towards Kv1.3 and Kv1.2 but not Kv1.1 channels expressed in oocytes.
Abbas N; Belghazi M; Abdel-Mottaleb Y; Tytgat J; Bougis PE; Martin-Eauclaire MF
Biochem Biophys Res Commun; 2008 Nov; 376(3):525-30. PubMed ID: 18804453
[TBL] [Abstract][Full Text] [Related]
3. K
Kuzmenkov AI; Nekrasova OV; Peigneur S; Tabakmakher VM; Gigolaev AM; Fradkov AF; Kudryashova KS; Chugunov AO; Efremov RG; Tytgat J; Feofanov AV; Vassilevski AA
Neuropharmacology; 2018 Dec; 143():228-238. PubMed ID: 30248306
[TBL] [Abstract][Full Text] [Related]
4. High-throughput screening for Kv1.3 channel blockers using an improved FLIPR-based membrane-potential assay.
Liu K; Samuel M; Tillett J; Hennan JK; Mekonnen B; Soloveva V; Harrison RK; Paslay JW; Larocque J
J Biomol Screen; 2010 Feb; 15(2):185-95. PubMed ID: 20044579
[TBL] [Abstract][Full Text] [Related]
5. Arrangement of Kv1 alpha subunits dictates sensitivity to tetraethylammonium.
Al-Sabi A; Shamotienko O; Dhochartaigh SN; Muniyappa N; Le Berre M; Shaban H; Wang J; Sack JT; Dolly JO
J Gen Physiol; 2010 Sep; 136(3):273-82. PubMed ID: 20805574
[TBL] [Abstract][Full Text] [Related]
6. Subtype-specific block of voltage-gated K
Leipold E; Ullrich F; Thiele M; Tietze AA; Terlau H; Imhof D; Heinemann SH
Biochem Biophys Res Commun; 2017 Jan; 482(4):1135-1140. PubMed ID: 27916464
[TBL] [Abstract][Full Text] [Related]
7. In Vitro electrophysiological activity of nerispirdine, a novel 4-aminopyridine derivative.
Smith C; Kongsamut S; Wang H; Ji J; Kang J; Rampe D
Clin Exp Pharmacol Physiol; 2009 Nov; 36(11):1104-9. PubMed ID: 19413590
[TBL] [Abstract][Full Text] [Related]
8. Ion channel pharmacology under flow: automation via well-plate microfluidics.
Spencer CI; Li N; Chen Q; Johnson J; Nevill T; Kammonen J; Ionescu-Zanetti C
Assay Drug Dev Technol; 2012 Aug; 10(4):313-24. PubMed ID: 22574656
[TBL] [Abstract][Full Text] [Related]
9. Differential contributions of voltage-gated potassium channel subunits in enhancing temporal coding in the bushy cells of the ventral cochlear nucleus.
Fu M; Zhang L; Xie X; Wang N; Xiao Z
J Neurophysiol; 2021 May; 125(5):1954-1972. PubMed ID: 33852808
[TBL] [Abstract][Full Text] [Related]
10. High-throughput electrophysiological assays for voltage gated ion channels using SyncroPatch 768PE.
Li T; Lu G; Chiang EY; Chernov-Rogan T; Grogan JL; Chen J
PLoS One; 2017; 12(7):e0180154. PubMed ID: 28683073
[TBL] [Abstract][Full Text] [Related]
11. Functional changes in genetically dysmyelinated spinal cord axons of shiverer mice: role of juxtaparanodal Kv1 family K+ channels.
Sinha K; Karimi-Abdolrezaee S; Velumian AA; Fehlings MG
J Neurophysiol; 2006 Mar; 95(3):1683-95. PubMed ID: 16319208
[TBL] [Abstract][Full Text] [Related]
12. Rearrangement of potassium ions and Kv1.1/Kv1.2 potassium channels in regenerating axons following end-to-end neurorrhaphy: ionic images from TOF-SIMS.
Liu CH; Chang HM; Wu TH; Chen LY; Yang YS; Tseng TJ; Liao WC
Histochem Cell Biol; 2017 Oct; 148(4):407-416. PubMed ID: 28405806
[TBL] [Abstract][Full Text] [Related]
13. Scorpion Potassium Channel-blocking Defensin Highlights a Functional Link with Neurotoxin.
Meng L; Xie Z; Zhang Q; Li Y; Yang F; Chen Z; Li W; Cao Z; Wu Y
J Biol Chem; 2016 Mar; 291(13):7097-106. PubMed ID: 26817841
[TBL] [Abstract][Full Text] [Related]
14. Engineering-specific pharmacological binding sites for peptidyl inhibitors of potassium channels into KcsA.
Legros C; Schulze C; Garcia ML; Bougis PE; Martin-Eauclaire MF; Pongs O
Biochemistry; 2002 Dec; 41(51):15369-75. PubMed ID: 12484776
[TBL] [Abstract][Full Text] [Related]
15. Structural basis of a potent peptide inhibitor designed for Kv1.3 channel, a therapeutic target of autoimmune disease.
Han S; Yi H; Yin SJ; Chen ZY; Liu H; Cao ZJ; Wu YL; Li WX
J Biol Chem; 2008 Jul; 283(27):19058-65. PubMed ID: 18480054
[TBL] [Abstract][Full Text] [Related]
16. Electrophysiological analysis of mammalian cells expressing hERG using automated 384-well-patch-clamp.
Haraguchi Y; Ohtsuki A; Oka T; Shimizu T
BMC Pharmacol Toxicol; 2015 Dec; 16():39. PubMed ID: 26671227
[TBL] [Abstract][Full Text] [Related]
17. Development of a selective inhibitor for Kv1.1 channels prevalent in demyelinated nerves.
Al-Sabi A; Daly D; Rooney M; Hughes C; Kinsella GK; Kaza SK; Nolan K; Oliver Dolly J
Bioorg Chem; 2020 Jul; 100():103918. PubMed ID: 32428746
[TBL] [Abstract][Full Text] [Related]
18. Novel, potent inhibitors of human Kv1.5 K+ channels and ultrarapidly activating delayed rectifier potassium current.
Lagrutta A; Wang J; Fermini B; Salata JJ
J Pharmacol Exp Ther; 2006 Jun; 317(3):1054-63. PubMed ID: 16522807
[TBL] [Abstract][Full Text] [Related]
19. Kv1 potassium channel C-terminus constant HRETE region: arginine substitution affects surface protein level and conductance level of subfamily members differentially.
Zhu J; Gomez B; Watanabe I; Thornhill WB
Mol Membr Biol; 2007; 24(3):194-205. PubMed ID: 17520476
[TBL] [Abstract][Full Text] [Related]
20. Inhibitory action of fluvoxamine on Kv1.5 currents.
Lee HM; Hahn SJ; Choi BH
Biol Pharm Bull; 2010; 33(6):977-82. PubMed ID: 20522962
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
